Clinical Trial

Ipilimumab for Head and Neck Cancer Patients

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-06-21; most recent amendment 2026-04-21.
Status change: Recruiting → Active, Not Recruiting 2023-01-08
Status change: Not Yet Recruiting → Recruiting 2017-06-13
Trial Details
NCT Number NCT02812524
Lead Sponsor Providence Health & Services
Collaborators: Bristol-Myers Squibb
Conditions Squamous Cell Carcinoma of the Head and Neck
Enrollment 18 participants
Start Date 2016-11-18
Primary Completion 2019-09-21 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24